The key in making coverage decisions about the integration of immuno-oncology agents into payment plans is being able to identify the patients who are most likely to benefit while also considering the long-term need for the acceptance of innovation in cancer care when faced with economic constraints, said Michael Kolodziej, MD, national medical director for oncology strategy at Aetna.
The key in making coverage decisions about the integration of immuno-oncology agents into payment plans is being able to identify the patients who are most likely to benefit while also considering the long-term need for the acceptance of innovation when faced with economic constraints, said Michael Kolodziej, MD, former national medical director for oncology strategy at Aetna.
Transcript (slightly modified)
How does Aetna expect to integrate the new immuno-oncology agents into payment programs and pathways?
So there’s kind of 2 separate parts here. One part is about immuno-oncology and the promise that immuno-oncology offers. And so like every other covered benefit, we have a certain set of rules that we will be forced to really employ as we make coverage decisions. As an oncologist, they’re tremendously exciting drugs.
I think the potential will only fully be tapped by the ability to identify patients most likely to benefit. And so I say this all the time: we are in such desperate need for the development of biological markers to predict response or, alternatively, to predict a lack of response because lack of response is important. It identifies patients with toxicity cost, financial cost, and opportunity cost. I think we’re going to manage them, at least in the short term, like we manage everything else.
I think in the long term, the question is more about innovation and how we accomplish the acceptance and dissemination of innovation in cancer care when we’re faced with economic constraints, the reality of the increasing cost of care, and although I don’t have the answer to that question right now, we need to keep a couple things in mind.
One, is we that we need to have intellectual honesty and not hype. I am completely aware of the desperation that patients with cancer find themselves. I totally get it. I think our job is to try to get the patient the right treatment and the best outcome, and worry about the cost in the context of really targeting that therapy to the right population, personalizing the care for that population. It gets a lot easier to consider the budgetary impact of an expensive immuno-oncology drug if 70% of patients are not going to benefit, if you’re not treating those patients, right? It does no patient good to receive therapy that is ultimately going to be ineffective and no patient is interested in receiving therapy that’s ineffective. So that should be a nice common ground where we find ourselves.
Ultimately, we are going to have to face the challenges with the cost of innovation, and what’s the fair cost of innovation, and how we pay for that, but we have some low-hanging fruit that we can tackle first.
Standard Criteria for Loss of Ambulation Needed in DMD
April 19th 2024A recent study suggests the differences between ambulation definitions for patients with Duchenne muscular dystrophy (DMD) can impact the identification of ambulant vs nonambulant individuals, and standard criteria across settings are needed.
Read More
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Government agencies have created an online portal for the public to report potential anticompetitive practices in health care; there are changes coming to the “boxed warning” section for chimeric antigen receptor T-cell therapies (CAR T) to highlight T-cell blood cancer risk; questions about the safety of obesity medications during pregnancy have arisen in women on them who previously struggled with fertility issues.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More